NorDiag has decided to exercise the previously announced option for exclusive commercial rights for a new DNA analysis method for cancer diagnostics. The company has now obtained satisfactory indications that the new method enables development of a cost effective and scalable test to screen for colorectal cancer. NorDiag will also review possible integration of the acquired technology in Genefec to further improve the performance of the company’s diagnostic test.

NorDiag announced 23 October 2006 that the company had secured international commercial rights for a new DNA analysis method for cancer diagnostics. These rights were initially secured through an option. Now based on internal evaluation of the method’s capabilities, the company has decided to exercise the option and has concluded an agreement to utilise this method.

– Combined with our own patents and previously secured licenses, this represents another important step on the way to making the company a leading genetic test supplier within colorectal cancer screening and diagnostics, says CEO Christian Horn.

The market for screening of colorectal cancer in Europe is large. In the UK, the health authorities have allocated GBP 37.5 million for the next two years, targeting 2 million tests annually. Applying the same assumptions as for the UK, the market in Western Europe would amount to some 12 million tests annually.

Screening programmes for colorectal cancer are currently being conducted with FOBT (Faecal Occult Blood Tests) tests. NorDiag’s Screenfec, which is under development, is expected to be considerably more precise than FOBT, and can thus reduce both costs for the authorities and the number of false positive tests for patients who have to undergo unnecessary follow-up examinations . The company is currently involved in pilot studies for screening programs in Scotland and in Tuscany (Italy).

For further information, please see www.nordiag.no or contact;
CEO Christian Horn in NorDiag ASA, tel: +47 90163153

About NorDiag
NorDiag is a biotechnology company with focus on early detection of cancer. The company’s first products are Genefec and GeneOpsy, for genetic diagnostics of colorectal cancer. In addition the company has R&D programmes for new technology and products for lung- and pancreatic cancer. NorDiag is listed on the Oslo Stock Exchange with the ticker NORD.